ESR1 and cancer: Interestingly, despite possible differences in cancer screening; demographics, including race and ethnicity; and use of treatments that may affect 5-year breast cancer mortality, all these studies, including ours, reported an overestimation of mortality for estrogen receptor–negative cancers, suggesting that other unmeasured factors may also play a role.